91 percent response rate for venetoclax against newly diagnosed AML in older adults

Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news